Pfizer Archives - Pharmaphorum

FDA approves Pfizer’s Besponsa in aggressive blood cancer

August 18, 2017

Besponsa becomes first of its kind indicated for rare type of acute lymphoblastic leukaemia.

FDA approves Pfizer’s Besponsa in aggressive blood cancer

https://pharmaphorum.com/news/pfizer-besponsa-leukaemia/

The curious case of Mylotarg: Pfizer’s leukaemia drug set to return

July 12, 2017

Mylotarg backed by advisers after withdrawal in 2010.

The curious case of Mylotarg: Pfizer’s leukaemia drug set to return

https://pharmaphorum.com/news/pfizer-mylotarg-looks-set-return/

Novartis CAR-T safety in FDA spotlight

July 11, 2017

FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to

Novartis CAR-T safety in FDA spotlight

https://pharmaphorum.com/news/fda-advisers-consider-novartis-car-t-safety/

Pfizer facing NICE showdown over leukaemia drug

July 3, 2017

Pfizer locks horns with NICE following EU approval.

Pfizer facing NICE showdown over leukaemia drug

https://pharmaphorum.com/news/pfizer-facing-nice-showdown-drug/

NICE green light a win for Lilly in RA market

June 30, 2017

RA drug backed after manufacturer offered discount.

NICE green light a win for Lilly in RA market

https://pharmaphorum.com/news/lillys-olumiant-recommended-nice/

NICE recommends Sanofi’s Gaucher treatment

June 28, 2017

Cancer drugs from Novartis and Pfizer also backed

NICE recommends Sanofi’s Gaucher treatment

https://pharmaphorum.com/news/nice-recommends-sanofis-gaucher-treatment/

Kisqali set for approval – but likely to hit same NICE obstacles as rival

June 28, 2017

Concerns that NICE will reject Kisqali like it did Ibrance.

Kisqali set for approval – but likely to hit same NICE obstacles as rival

https://pharmaphorum.com/news/will-patients-access-novartis-breast-cancer-drug-england/

FDA fast-tracks Lilly/Pfizer pain drug amid opioid crisis

June 15, 2017

Companies hope tanezumab offers alternative to opioids

FDA fast-tracks Lilly/Pfizer pain drug amid opioid crisis

https://pharmaphorum.com/news/lillypfizer-pain-drug-gets-fda-fast-review/

Merck, Pfizer covering bases with SGLT2 inhibitor latecomer

June 12, 2017

This year’s American Diabetes Association conference takes place right next to San Diego’s baseball stadium – and like

Merck, Pfizer covering bases with SGLT2 inhibitor latecomer

https://pharmaphorum.com/news/merck-pfizer-cover-bases-sglt2-inhibitor/

Trending

Pfizer

FDA approves Pfizer’s Besponsa in aggressive blood cancer

The curious case of Mylotarg: Pfizer’s leukaemia drug set to return

Novartis CAR-T safety in FDA spotlight

Pfizer facing NICE showdown over leukaemia drug

NICE green light a win for Lilly in RA market

NICE recommends Sanofi’s Gaucher treatment

Kisqali set for approval – but likely to hit same NICE obstacles as rival

FDA fast-tracks Lilly/Pfizer pain drug amid opioid crisis

Merck, Pfizer covering bases with SGLT2 inhibitor latecomer

7th Annual Partnership Opportunities in Drug Delivery (PODD)

2nd Annual RNA Therapeutics Summit

3rd Annual Pre-Filled Syringes Summit

Mylan finalises $465m deal with US government over EpiPen

FDA approves Pfizer’s Besponsa in aggressive blood cancer

AZ and Merck & Co ovarian cancer drug gets expanded US use

UCB recruits Belgian wearables firm for epilepsy study

Trump disbands business forums as CEOs quit

Digital health round-up: Apple vs Google

Spotlight on: The Future of Medical Affairs

AZ looks to pay-for-performance to bolster cardio-diabetes franchise

Medical Affairs – the heart of a data-driven, patient-centric pharma

Five questions: How are data and analytics transforming Medical Affairs?

Search

Advanced Search

Trending

Pfizer